Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Genprex Inc (NQ: GNPX )

3.740 USD -0.010 (-0.27%)
Streaming Delayed Price Updated: 11:01 AM EST, Jan 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Genprex Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors
Genprex Adds Dr. John Bonfiglio to Board of Directors. 
From Business Wire News Releases
Genprex to Present at NobleConXV in Fort Lauderdale, Florida
Genprex Will Present and Participate in Panel Discussion at Upcoming NobleConXV Conference 
From Business Wire News Releases
Genprex to Present at Biotech Showcase™ 2019 in San Francisco
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present... 
From Business Wire News Releases
The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags CKPT ORPN SRNE
From Benzinga
Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019
Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be... 
From Business Wire News Releases
Genprex to Present at the 11th Annual LD Micro Main Event
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that its Chairman... 
From Business Wire News Releases
The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags EBS NK IMGN
From Benzinga
Genprex Provides Clinical and Corporate Update for Third Quarter 2018
Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and... 
From Business Wire News Releases
The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags Benzinga TTPH EVLO
From Benzinga
Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations
Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of... 
From Business Wire News Releases
The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting ... 
Tags MRS ADXS LOGC
From Benzinga
The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program
Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical ... 
Tags TRVN MGEN Top Stories
From Benzinga
The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting ... 
Tags VCYT GRTS MOR
From Benzinga
The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting ... 
Tags GNPX Benzinga News
From Benzinga
The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting ... 
Tags Trading Ideas IBB MMSI
From Benzinga
Genprex to Present at Upcoming Investor and Industry Conferences
Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management... 
From Business Wire News Releases
Analysts Forecast 22% Gains Ahead For IWC
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program
Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with... 
From Business Wire News Releases
The Week Ahead: Nike Earnings, FDA Debates E-Cig Industry, SurveyMonkey IPOs
Below is a list of notable corporate events for the week beginning Sept. 24. Note, this list is not comprehensive and all dates are ... 
Tags CRM Trading Ideas MSFT
From Benzinga
44 Biggest Movers From Friday
Gainers Qutoutiao Inc. (NASDAQ: QTT) shares surged 128.14 percent to close at $15.97 on Friday. Qutoutiao announced an initial ... 
Tags NMRD FEIM CDAY
From Benzinga
32 Stocks Moving In Friday's Mid-Day Session
Gainers Frequency Electronics, Inc. (NASDAQ: FEIM) shares gained 17 percent to $9.21. Frequency Electronics reported Q1 net ... 
Tags IRIX Movers KNDI
From Benzinga
Benzinga's Top Upgrades, Downgrades For September 14, 2018
Top Upgrades Citigroup upgraded Corning Incorporated (NYSE: GLW) from Neutral to Buy. Corning shares rose 2.37 percent to $35.89 ... 
Tags Initiation PRSP COST
From Benzinga
26 Stocks Moving In Tuesday's Pre-Market Session
Gainers Genprex, Inc. (NASDAQ: GNPX) rose 17.7 percent to $3.00 in pre-market trading. Restoration Robotics, Inc. (NASDAQ: HAIR) ... 
Tags JD Movers SESN
From Benzinga
40 Biggest Movers From Yesterday
Gainers Affimed N.V. (NASDAQ: AFMD) shares climbed 246.88 percent to close at $5.55 on Tuesday after the clinical stage ... 
Tags BBY RIGL MITK
From Benzinga
Genprex Amends Options to License Additional Cancer Fighting Technologies from the University of Texas MD Anderson Cancer Center
Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered... 
From Business Wire News Releases
The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks hitting ... 
Tags FDA INSP VSTM
From Benzinga
The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags Earnings MEDP AVNS
From Benzinga
Genprex to Present at Upcoming Investor Conferences
Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that company... 
From Business Wire News Releases
Genprex Provides Clinical and Corporate Update for Second Quarter 2018
Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and... 
From Business Wire News Releases
Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung C
Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it has amended... 
From Business Wire News Releases
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.